LAVA Therapeutics NV
LVTXDelisted Nov 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840748
LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.
13F holders, Q2 2023
Institutional positions in LAVA Therapeutics NV as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- −4 vs. Q1 2023
- Shares held
- 5.75M
- −993.0K (−14.7%) vs. Q1 2023
- Total value
- $11.7M
- +$476.1K (+4.3%) vs. Q1 2023
- New holders
- 5
- 3 more added
- Sold out
- 9
- 2 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 21 | $16.1M |
| Q2 2025 | 19 | $10.6M |
| Q1 2025 | 20 | $10.2M |
| Q4 2024 | 22 | $6.15M |
| Q3 2024 | 21 | $5.99M |
| Q2 2024 | 19 | $6.77M |
| Q1 2024 | 20 | $12.5M |
| Q4 2023 | 14 | $9.22M |
| Q3 2023 | 14 | $8.47M |
| Q2 2023 | 15 | $11.7M |
| Q1 2023 | 19 | $11.2M |
| Q4 2022 | 20 | $26.3M |
| Q3 2022 | 13 | $34.1M |
| Q2 2022 | 17 | $22.8M |
| Q1 2022 | 18 | $35.2M |
| Q4 2021 | 20 | $44.3M |
| Q3 2021 | 19 | $48.6M |
| Q2 2021 | 18 | $95.5M |
| Q1 2021 | 24 | $139.1M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Novo Holdings A/S | 2,400,000 | $4.87M | 0.38% | −670,558−21.8% | Reduced |
| Redmile Group, LLC | 2,074,372 | $4.21M | 0.16% | 00.0% | Unchanged |
| Bruce & Co., Inc. | 771,874 | $1.57M | 0.44% | +100,000+14.9% | Added |
| Artal Group S.A. | 200,000 | $406.0K | 0.01% | 00.0% | Unchanged |
| Falcon Edge Capital, LP | 109,097 | $221.5K | 0.15% | −10,419−8.7% | Reduced |
| Millennium Management LLC | 80,374 | $163.2K | 0.00% | +80,374 | New |
| The PNC Financial Services Group, Inc. | 65,000 | $131.9K | 0.00% | +15,000+30.0% | Added |
| Tower Research Capital LLC (TRC) | 11,960 | $24.3K | 0.00% | +11,960 | New |
| Geode Capital Management, LLC | 11,124 | $22.6K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 10,714 | $21.0K | 0.00% | +10,714 | New |
| Morgan Stanley | 10,200 | $20.7K | 0.00% | +1,300+14.6% | Added |
| Simplex Trading, LLC | 1,142 | $2.00K | 0.00% | +1,142 | New |
| TSFG, LLC | 400 | $1.00K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 100 | $203 | 0.00% | +100 | New |
| Advisor Group Holdings, Inc. | 48 | $97 | 0.00% | 00.0% | Unchanged |
| AXA S.A. | 0 | $0 | 0.00% | −225,748−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −140,291−100.0% | Sold out |
| Cantor Fitzgerald, L. P. | 0 | $0 | 0.00% | −53,299−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −32,240−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −27,898−100.0% | Sold out |
| UBS Oconnor LLC | 0 | $0 | 0.00% | −20,502−100.0% | Sold out |
| Cannell Capital LLC | 0 | $0 | 0.00% | −17,955−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −10,600−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −4,095−100.0% | Sold out |